关键要点
Photodynamic therapy (PDT) is one of the most effective options for chronic central serous chorioretinopathy (CSCR). Central serous chorioretinopathy treatment with PDT can significantly reduce fluid leakage and improve visual outcomes. While generally safe, PDT carries potential risks such as retinal damage and temporary visual disturbances. Careful patient selection and monitoring are essential to maximize the benefits of central serous chorioretinopathy treatment.
慢性中央水肿性脉络膜视网膜病变（CSCR）是一种视网膜疾病，其特征是黄斑下持续积液，导致视力模糊或视物变形。与急性病例不同，慢性CSCR通常需要积极干预以防止长期损伤[1]。
Photodynamic therapy is an effective central serous chorioretinopathy treatment that reduces choroidal leakage and improves vision, but it also carries certain risks that must be carefully considered. Understanding both the benefits and potential complications of PDT helps patients make informed decisions about their care.
什么是光动力疗法？
光动力疗法是一种用于治疗眼部异常血管的微创手术。该疗法包括注射光敏药物（通常为维替泊芬），随后使用低能量激光照射患处以激活药物[2]。在治疗中心性浆液性脉络膜视网膜病变时，光动力疗法的作用机制包括[3]：
- 降低脉络膜血管通透性
- 封闭渗漏的血管
- 促进视网膜下液体的再吸收
这种靶向治疗方法使PDT在慢性病例中尤为有效，即在观察期间液体仍持续存在的情况下。
光动力疗法的优势
1. 对慢性病例疗效显著
PDT被广泛认为是治疗慢性或复发性中央浆液性脉络膜视网膜病变（CSCR）最有效的方法之一。许多患者在治疗后液体显著减少，视力得到改善[4]。
2. 靶向治疗方法
Unlike systemic medications, PDT acts directly on the affected area, minimizing impact on surrounding tissues. This precision enhances the safety and effectiveness of central serous chorioretinopathy treatment.
3. 降低复发率
By addressing the underlying choroidal abnormalities, PDT can lower the likelihood of recurrence, making it a valuable long-term 中央浆液性脉络膜视网膜病变治疗方案.
4. 微创手术
该手术可在门诊进行，通常无需切口且恢复时间较短，为患者提供了便利。
风险与潜在并发症
Despite its benefits, PDT is not without risks. Patients undergoing CSCR治疗， with PDT should be aware of possible complications.
- Retinal Damage: Excessive laser exposure or improper dosing may cause damage to the retina, potentially affecting vision [5].
- Temporary Visual Disturbances: Some patients experience temporary blurred vision or changes in visual perception following treatment [6].
- Choroidal Ischemia: In rare cases, PDT may reduce blood flow to the choroid, leading to tissue damage.
- Photosensitivity Reactions: Because the drug used in PDT is light-sensitive, patients must avoid direct sunlight for a period after treatment to prevent skin reactions.
Although these risks exist, they are relatively uncommon when the procedure is performed correctly as part of central serous chorioretinopathy treatment.
哪些患者适合接受治疗？
光动力疗法通常推荐用于以下患者：
- 持续性视网膜下积液（超过3–6个月）
- 中央浆液性脉络膜视网膜病变（CSCR）复发
- 视力受损影响日常生活
Not all patients are ideal candidates. The decision to use PDT as a 中心性视网膜炎的管理 depends on factors such as lesion location, disease severity, and overall eye health.
治疗流程概述
光动力疗法（PDT）包含以下几个步骤：
- 静脉注射光敏剂
- 等待药物在体内循环
- 对受影响的视网膜区域照射低能量激光
The entire procedure typically takes less than an hour. Patients undergoing CSCR treatment with PDT can usually return home the same day.
康复与术后护理：
光动力疗法的恢复通常较快，但仍需采取某些预防措施。建议患者：
- 48小时内避免阳光直射
- 穿戴防护服和太阳镜
- 监测视力变化
- 按时复诊
These steps help ensure the success of central serous chorioretinopathy treatment 并降低并发症的风险。
益处与风险的比较
| 方面 | 好处 | 风险/局限性 |
| 疗效 | 在减少玻璃体积方面成功率高 | 可能需要重复治疗 |
| 安全性 | 微创 | 罕见视网膜或脉络膜损伤 |
| 恢复 | 恢复时间短 | 暂时性畏光 |
| 长期预后 | 降低复发率 | 不适合所有患者 |
光动力疗法的替代方案
While PDT is highly effective, other options may be considered depending on the patient’s condition. Alternative central serous chorioretinopathy treatment 方案包括：
- 亚阈值激光治疗
- 药物治疗（例如依普利酮）
- 轻症病例的观察随访
每种方案各有其优势和局限性，治疗应根据个体情况量身定制。
早期治疗的重要性
Early intervention is key to preventing long-term damage in chronic CSCR. Delayed treatment can lead to permanent changes in the retina and reduced visual acuity. By initiating appropriate central serous chorioretinopathy treatment at the right time, patients can achieve better outcomes and preserve their vision.
长期预后
接受光动力疗法（PDT）治疗中心性浆液性脉络膜视网膜病变的患者，预后通常良好。许多患者的视力显著改善，症状也得到缓解。然而，由于部分病例可能复发，持续监测至关重要。定期随访有助于及时发现并处理任何病变变化。
结论
光动力疗法是治疗慢性中心性浆液性脉络膜视网膜病变（CSCR）的一种高效且广泛采用的方案。通过针对性治疗液体渗漏的根本原因，该疗法在改善视力和控制疾病方面具有显著优势。
尽管存在潜在风险，但这些风险相对罕见，且通过规范的操作技术和合理的患者筛选可将其降至最低。对于许多患者而言，光动力疗法是治疗中心性浆液性脉络膜视网膜病变的有效手段，有助于保护视力并改善生活质量。
参考文献
- Daruich, A., Matet, A., Dirani, A., Bousquet, E., Zhao, M., Farman, N., Jaisser, F., & Behar-Cohen, F. (2015). Central serous chorioretinopathy: Recent findings and new physiopathology hypothesis. Progress in Retinal and Eye Research, 48, 82–118. https://doi.org/10.1016/j.preteyeres.2015.05.003
- American Academy of Ophthalmology. (2024). Photodynamic therapy (PDT). https://www.aao.org/eye-health/treatments/photodynamic-therapy
- van Rijssen, T. J., van Dijk, E. H. C., Yzer, S., Ohno-Matsui, K., Keunen, J. E. E., Schlingemann, R. O., & Boon, C. J. F. (2019). Central serous chorioretinopathy: Towards an evidence-based treatment guideline. Progress in Retinal and Eye Research, 73, 100770. https://doi.org/10.1016/j.preteyeres.2019.07.003
- Yannuzzi, L. A., Slakter, J. S., Gross, N. E., Spaide, R. F., Costa, D., Huang, S. J., & Klancnik, J. M. (2003). Indocyanine green angiography-guided photodynamic therapy for chronic central serous chorioretinopathy. Ophthalmology, 110(7), 1348–1354. https://doi.org/10.1016/S0161-6420(03)00418-3
- Chan, W. M., Lai, T. Y. Y., Lai, R. Y. K., Liu, D. T. L., & Lam, D. S. C. (2003). Safety enhanced photodynamic therapy for chronic central serous chorioretinopathy: One-year results of a prospective study. Retina, 23(6), 750–756. https://doi.org/10.1097/00006982-200312000-00002
- National Health Service. (2023). Photodynamic therapy. https://www.nhs.uk/conditions/photodynamic-therapy/
